Differential effects of alendronate on chondrocytes, cartilage matrix and subchondral bone structure in surgically induced osteoarthritis in mice

Sci Rep. 2024 Oct 23;14(1):25026. doi: 10.1038/s41598-024-75758-7.

Abstract

Bisphosphonates (BP) are considered a treatment option for osteoarthritis (OA) due to reduction of OA-induced microtrauma in the bone marrow, stabilization of subchondral bone (SB) layer and pain reduction. The effects of high-dose alendronate (ALN) treatment on SB and articular cartilage after destabilization of the medial meniscus (DMM) or Sham surgery of male C57Bl/6J mice were analyzed. We performed serum analysis; histology and immunohistochemistry to assess the severity of OA and a possible pain symptomatology. Subsequently, the ratio of bone volume to total volume (BV/TV), epiphyseal trabecular morphology and the bone mineral density (BMD) was analyzed by nanoCT. Serum analysis revealed a reduction of ADAMTS5 level. The histological evaluation displayed no protective effect of ALN-treatment on cartilage erosion. NanoCT-analysis of the medial epiphysis revealed an increase of BV/TV in ALN-treated mice. Only the DMM group had significantly higher SB volume accompanied by decreased subchondral bone surface. Furthermore Nano-CT analysis revealed an increase in trabecular density and number, a decreased BMD and reduced osteophyte formation in the ALN mice. ALN treatment affected bone micro-architecture by reducing osteophytosis with simultaneous increasing subchondral bone plate thickness, trabecular thickness and BMD. Accordingly, ALN cannot be considered as a potential treatment strategy in general, however in a subgroup of patients with high bone turnover in an early-stage of OA, ALN might be an option when applied during a restricted time frame.

Keywords: ADAMTS-5; Alendronate; Bisphosphonate; Cartilage; Chondrocytes; DMM; MMP-13; Micro/nano-CT; NK1-R; Osteoarthritis; Osteoclasts; Subchondral bone; VDIPEN.

MeSH terms

  • ADAMTS5 Protein / metabolism
  • Alendronate* / pharmacology
  • Alendronate* / therapeutic use
  • Animals
  • Bone Density Conservation Agents / pharmacology
  • Bone Density Conservation Agents / therapeutic use
  • Bone Density* / drug effects
  • Bone and Bones / drug effects
  • Bone and Bones / pathology
  • Cartilage, Articular* / drug effects
  • Cartilage, Articular* / pathology
  • Chondrocytes* / drug effects
  • Chondrocytes* / metabolism
  • Chondrocytes* / pathology
  • Disease Models, Animal
  • Male
  • Mice
  • Mice, Inbred C57BL*
  • Osteoarthritis* / drug therapy
  • Osteoarthritis* / pathology

Substances

  • Alendronate
  • Bone Density Conservation Agents
  • ADAMTS5 Protein